Atorvastatin Calcium: An Addition to HMG‐CoA Reductase Inhibitors

Abstract

Atorvastatin calcium is an HMG‐coenzyme A (CoA) reductase inhibitor that was approved by the Food and Drug Administration on December 17, 1996. Like other such agents, it inhibits the action of HMG‐CoA reductase and thereby decreases endogenous cholesterol synthesis, leading to a decrease in circulating low‐density lipoprotein cholesterol. In addition to its effect on lipoprotein profile, atorvastatin reduces triglycerides to a greater extent than other HMG‐CoA reductase inhibitors. These actions occur in a dose‐dependent fashion. The adverse effect profile is similar to that of other agents in this class. Indications for atorvastatin include primary hypercholesterolemia as well as other lipid disorders.